European Commission approves Meropinan/vaborbactam treatment for adult patients with incurable infectious diseases

November 20, 2018, the European Commission approved the clinical application of Meropinan/vaborbactam to treat adult patients with difficult-to-cure infectious diseases
And more recently, the Menarini Group reached an agreement with Melintagrouptonics to commercialize Merropinan/vaborbactam in Europe, Asia Pacific and CISbased on the results of the TANGO Itrial(http://results, Merropin/vaborbactam was initially approved by the U.SFoodDrug(http://Administration for the treatment of adult complex urinary tract infections, including pyelone nephritisAbout VaborbactamVaborbactam is effective in its first Class A inhibitors (including CPC) of the pneumonia Crebelo carbapenem serotonin assylotose, which protects meroppenan from the degradation of certain serine carbide myomynaases and restores its resistance to carbon-resistant strainsIn the TANGO II trial, Merropinan/vaborbactam, as an intravenous monotherapy, improves clinical cure rates, reduces mortality and reduces treatment-related adverse events (e.grenal toxicity) compared to the best available therapiesStatistics show that higher cure rates also occur in immunodeficiency patients, who are often excluded from clinical trialsThe TANGO II trial, which gave thecompany(http://a European license, is the largest to date for patients with carbon-forymine-resistant Ecoli bacteria (CRE)results show that in addition to complex urinary tract infections (including phoronne phoritis), the clinical indications range of Meropinan/vaborbactam has been broadened to hospital access to pneumonia/respiratory-related bacterial pneumonia, complex intra-abdominal infections and these infection-related bacteremia